Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGM1812 in Overweight or Obese Participants Without Diabetes
NCT07918625Phase 2Not yet recruiting
- Sponsor
- BrightGene Bio-Medical Technology
- Start
- Nov 2026
- Primary completion
- Aug 2027
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of BGM1812 in obesity (4 arms), sponsored by BrightGene Bio-Medical Technology. Primary endpoint: Percent Change from Baseline in Body Weight at 24 weeks. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
BGM1812
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07918625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07918625.